Clinical Trials Directory

Trials / Completed

CompletedNCT01486498

Quality of Life and Health Economic Measurements in Allergic Patients Treated With Immunotherapy

Health Economic Analyses of Treatment Strategies for Allergic Respiratory Diseases

Status
Completed
Phase
Study type
Observational
Enrollment
571 (actual)
Sponsor
Aalborg University · Academic / Other
Sex
All
Age
16 Years
Healthy volunteers
Accepted

Summary

Grass pollen and house dust mites (HDM) are the most common allergens causing allergic rhino-conjunctivitis (RC) and/or asthma (A). Subcutaneous allergen specific immunotherapy (SCIT) reduces symptoms and use of medication. The purpose of SABAL is to assess the effect of SCIT on disease severity classifications in terms of number of days affected- and sick days on patients with grass pollen and/or HDM induced disease. These outcome measures will be gathered in one single measure: Quality Adjusted Life Years (QALY)

Conditions

Timeline

Start date
2005-11-01
Primary completion
2009-11-01
Completion
2011-11-01
First posted
2011-12-06
Last updated
2011-12-06

Source: ClinicalTrials.gov record NCT01486498. Inclusion in this directory is not an endorsement.